Meanwhile, HCC patients with low GDI2 expression could improve their prognosis when they were with clinicopathological subtypes as: T1 Stage (N=49, P = 0.010; HR (95%CI) = 2.18 (1.21-3.94); Figure 6D), negative lymph nodes (N=252, P < 0.001; HR (95%CI) = 2.252 (1.427-3.555); Figure 6E), without metastasis (N=266, P = 0.004; HR (95%CI) = 1.919 (1.232-2.990); Figure 6F), with fibrosis ishak score-1/2&3/4&5/6 (HR=2.56(1.24-5.25); P=0.011; Figure 6G); early pathologic stage I&II (HR=1.66(1.03-2.68); P=0.037; Figure 6H), and no vascular invasion (HR=2.23(1.32-3.76); P=0.003; Figure 6I). Here, GDI2 is linked to hepatocellular carcinoma.